Literature DB >> 21053151

PAIR technology: exon-specific RNA-binding protein isolation in live cells.

Thomas J Bell1, Emelía Eiríksdóttir, Ulo Langel, James Eberwine.   

Abstract

RNA-binding proteins (RBPs) are fundamental regulatory proteins for all forms of transcriptional and posttranscriptional control of gene expression. However, isolating RBPs is technically challenging for investigators. Currently, the most widely used techniques to isolate RBPs are in vitro biochemical approaches. Although these approaches have been useful, they have several limitations. One key limitation to using in vitro biochemical approaches is that RBP-RNA interactions are isolated under nonbiological conditions. Here we review a novel experimental approach to identify RBPs called peptide nucleic acid (PNA)-assisted identification of RBPs (PAIR) technology (Zielinski et al., Proc Natl Acad Sci USA 103:1557-1562, 2006). This technology has two significant advantages over traditional approaches. (1) It overcomes the in vitro limitation of biochemical approaches by allowing investigators to isolate RBP-RNA interactions under in vivo conditions. (2) This technology is highly mRNA specific; it isolates RBPs in an exon-specific manner. By selectively targeting alternatively spliced exons with PAIR technology, investigators can isolate splice variant-specific and mRNA region-specific (5-UTR and 3-UTR) RBP complexes for any mRNA of interest.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21053151     DOI: 10.1007/978-1-60761-919-2_34

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  3 in total

Review 1.  Probing Long Non-coding RNA-Protein Interactions.

Authors:  Jasmine Barra; Eleonora Leucci
Journal:  Front Mol Biosci       Date:  2017-07-11

Review 2.  Compendium of Methods to Uncover RNA-Protein Interactions In Vivo.

Authors:  Mrinmoyee Majumder; Viswanathan Palanisamy
Journal:  Methods Protoc       Date:  2021-03-19

Review 3.  Cell-Penetrating Peptides and Transportan.

Authors:  Ülo Langel
Journal:  Pharmaceutics       Date:  2021-06-29       Impact factor: 6.321

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.